April 17, 2012

Another Amyloid Tracer Shows Promise in Alzheimer’s


On the heels of the US Food and Drug Administration (FDA) approval of the amyloid tracer agent florbetapir (Amyvid, Eli Lilly), another biomarker is showing promise in detecting beta-amyloid deposition in the brains of living patients…Asked for his opinion, David Knopman, MD, Department of Neurology, Mayo Clinic, Rochester, Minnesota, said he found the accuracy of florbetaben to detect amyloid reported in this study to be "indeed encouraging."



Medscape by Pauline Anderson   4/17/12

Tags: Dr. David Knopman, florbetapir, Food and Drug Administration, Mayo Clinic Rochester, Neurology

Please sign in or register to post a reply.
Contact Us · Privacy Policy